Comparing the Cytokine Storms of COVID-19 and Pandemic Influenza

Abstract

Emerging respiratory viruses are major health threats due to their potential to cause massive outbreaks. Over the past 2 years, the coronavirus disease 2019 (COVID-19) pandemic has caused millions of cases of severe infection and deaths worldwide. Although natural and vaccine-induced protective immune mechanisms against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been increasingly identified, the factors that determine morbimortality are less clear. Comparing the immune signatures of COVID-19 and other severe respiratory infections such as the pandemic influenza might help dissipate current controversies about the origin of their severe manifestations. As such, identifying homologies in the immunopathology of both diseases could provide targets for immunotherapy directed to block shared pathogenic mechanisms. Meanwhile, finding unique characteristics that differentiate each infection could shed light on specific immune alterations exploitable for diagnostic and individualized therapeutics for each case. In this study, we summarize immunopathological aspects of COVID-19 and pandemic influenza from the perspective of cytokine storms as the driving force underlying morbidity. Thereby, we analyze similarities and differences in the cytokine profiles of both infections, aiming to bring forward those molecules more attractive for translational medicine and drug development.

In vitro evidence against productive SARS-CoV-2 infection of human testicular cells: Bystander effects of infection mediate testicular injury

“…Mild and severe COVID-19 patients exhibit systemic cytokine profiles similar to other infectious diseases such as Ebola virus disease (EVD) [ 53 ]. Systemic cytokine storm is also well described in influenza-infected patients and a recent study compared the cytokine profile with COVID-19 patients [ 54 ]. The data shows that cytokines like IL-6, TNF-a, and IL-1β are produced by both the influenza virus and SARS-CoV-2, though levels are higher in COVID-19 patients.…”

Inactivated SARS-CoV-2 Reprograms the Tumor Immune Microenvironment and Improves Murine Cancer Outcomes

“…Our study on intratumoral injection of heat-inactivated influenza virus as an immunotherapy agent was immediately followed by the onset of the COVID-19 pandemic. The rapid spread of SARS-CoV-2 established itself as a highly immunogenic virus, with notable similarities to influenza, including both viruses are single-stranded RNA viruseses 2 . Both viruses infect the respiratory tract and use surface proteins to infect the host.…”

Polymeric Materials as Indispensable Tools to Fight RNA Viruses: SARS-CoV-2 and Influenza A

“…In their work, they described the conception of a long-lasting (4-6 h), absorbent, osmotic, glycerol-based polymeric film using an in vitro nasal mucosa-mimicking model, containing polymers capable of not only cleaning the nasal surface, but also neutralizing pro-inflammatory cytokines and the COVID-19 S protein (Covispray) [89]. Cytokines are responsible for the activation, regulation and amplification of the immune response and their production is usually highly regulated in order to prevent systemic damage [90]. However, during viral infection, there may be significant pro-inflammatory cytokine expression, so-called "cytokine storm" (CS), which can result in inflammatory cell recruitment (associated with immune dysregulation, inflammation and hypercytokinemia [91]) and even lung tissue damage [92,93].…”